7022-37-9

Usage

Uses

Used in Pharmaceutical Industry:
2H-Benzimidazol-2-one,1,3-dihydro-1-methyl-,hydrazone(9CI) is used as a pharmaceutical compound for its potential therapeutic applications. The presence of the hydrazone functional group may allow it to form stable complexes with metal ions, which can be useful in the development of drugs targeting various diseases.
Used in Agrochemical Industry:
In the agrochemical industry, 2H-Benzimidazol-2-one,1,3-dihydro-1-methyl-,hydrazone(9CI) may be utilized as a component in the development of pesticides or herbicides. Its heterocyclic structure and functional groups could provide specific modes of action against pests or unwanted plant species.
Used in Materials Science:
2H-Benzimidazol-2-one,1,3-dihydro-1-methyl-,hydrazone(9CI) could be employed in materials science for the development of new materials with unique properties. Its heterocyclic structure and functional groups may contribute to the formation of polymers or other materials with specific characteristics, such as conductivity, stability, or reactivity.

InChI:InChI=1/C8H10N4/c1-12-7-5-3-2-4-6(7)10-8(12)11-9/h2-5H,9H2,1H3,(H,10,11)

Upstream product

• 1622-57-7 2-Amino-1-methylbenzimidazole 
• 4760-34-3 N-methyl-1,2-phenylenediamine 
• 1849-01-0 1-methyl-2-benzimidazolone 
• 1849-02-1 2-chloro-1-methyl-benzimidazole 
• 4857-06-1 2-chloro-1H-benzoimidazole 

Downstream Products

• 2165-12-0 9-Methyl-S-triazolo<4,3-a>benzimidazol-3-thion 
• 120513-41-9 N-methyl-2-(5-trifluoromethyl-3-phenyl-1H-pyrazol-1-yl)benzimidazole 
• 115153-89-4 N-Phenyl-2-(1-methylbenzimidazol-2-yl)hydrazinocarbothioamide 
• 115153-90-7 C₁₅H₁₄ClN₅S 
• 120513-38-4 2-[3-(4-Fluoro-phenyl)-5-pentafluoroethyl-pyrazol-1-yl]-1-methyl-1H-benzoimidazole 
• 1849-02-1 2-chloro-1-methyl-benzimidazole 
• 53114-97-9 N-benzylidene-N'-(1-methylbenzimidazol-2-yl)hydrazine 
• 1516-73-0 2-azido-1-methyl-1H-benzo[d]imidazole 
• 384843-95-2 5-bromo-2-hydroxyisophthalaldehyde bis[(1-methyl-1H-benzimidazol-2-yl)hydrazone] 
• 1445800-05-4 2-chloro-5-(5-(1-(2-(1-methyl-1H-benzimidazol-2-yl)hydrazono)ethyl)furan-2-yl)benzoic acid 
• 663216-50-0 C₂₂H₂₁N₅O₂S 
• 1338825-03-8 C₂₇H₂₁F₃N₄O₃S 
• 1338824-81-9 C₂₃H₂₀N₄O 
• 1338824-93-3 C₂₅H₂₂N₄O₂S 

Relevant academic research and scientific papers

Novel small molecular compound ae-848 potently induces human multiple myeloma cell apoptosis by modulating the nf-κb and pi3k/ akt/mtor signaling pathways

Background: We aimed to investigate the anti-multiple myeloma (MM) activity of the new small molecular compound AE-848 (5-bromo-2-hydroxyisophthalaldehyde bis[(1-methyl-1H-benzimidazol-2-yl)hydrazone]) and its underlying anti-MM mechanism. Methods: Cell viability and apoptosis were detected and quantified by using MTT and flow cytometry, respectively. JC-1 dye-related techniques were used to assess mitochondrial membrane potential (MMP). Western blotting was applied to detect the expression of NF-κB and PI3K/Akt/mTOR pathway-associated proteins. The in vivo activity of AE-848 against MM was evaluated in a MM mouse model. Results: Application of AE-848 into the in vitro cell culture system significantly reduced the viability and induced apoptosis of the MM cell lines, RPMI-8226 and U266, in a dose-and time-dependent manner, respectively. JC-1 dye and Western blotting analysis revealed that AE-848 induced the cleavage of caspase-8, caspase-3, and poly ADP-ribose polymerase (PARP), resulting in loss of mitochondrial membrane potential (MMP). Both the NF-κB and PI3K/AKT/mTOR signaling pathways were involved in AE-848-induced apoptosis of U266 and RPMI8226 cells. Moreover, AE-848 leads to cell cycle arrest of MM cells. Its anti-MM efficacy was further confirmed in a xenograft model of MM. AE-848 administration significantly inhibited MM tumor progression and prolonged the survival of MM-bearing mice. More importantly, our results demonstrated that AE-848 markedly induced primary MM cell apoptosis. Conclusion: Our results for the first time showed that the small compound AE-848 had potent in vitro and in vivo anti-myeloma activity, indicating that AE-848 may have great potential to be developed as a drug for MM treatment.

CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF

Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.

Antitumor compound, method for synthesizing same and application of antitumor compound

The invention provides an antitumor compound. A chemical name of the antitumor compound is 5-bromine-2-hydroxyl isophthalaldehyde di-[(1-methyl-1H-benzimidazole-2-group) hydrazone]. The antitumor compound which is an antitumor medicine can be used for pre

SMALL MOLECULE REGULATORS OF STEROID RECEPTOR COACTIVATORS AND METHODS OF USE THEREOF

Small molecule regulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing SRC-related diseases. The SRC-related diseases can include cancer, metabolic disorders, human immunodeficiency virus, neurodegenerative disorders, and/or inflammatory diseases. Also provided are methods for regulating SRC family proteins in a cell.

Design and synthesis of prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors as anti-prostate cancer drugs

A series of 1-aryl-3,4-substituted-1H-pyrazol-5-ol derivatives was synthesized and evaluated as prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors to obtain a novel anti-prostate cancer drug. After modifying 1-(1H-benzimidazol-2-yl)-3,4-dimethyl-1H-pyrazol-5-ol (1), a hit compound found during random screening using a recombinant PCA-1/ALKBH3, 1-(1H-5- methylbenzimidazol-2-yl)-4-benzyl-3-methyl-1H-pyrazol-5-ol (35, HUHS015), was obtained as a potent PCA-1/ALKBH3 inhibitor both in vitro and in vivo. The bioavailability (BA) of 35 was 7.2% in rats after oral administration. As expected, continuously administering 35 significantly suppressed the growth of DU145 cells, which are human hormone-independent prostate cancer cells, in a mouse xenograft model without untoward effects.

Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL

Developing potent molecules that inhibit Bcl-2 family mediated apoptosis affords opportunities to treat cancers via reactivation of the cell death machinery. We describe the hit-to-lead development of selective Bcl-X L inhibitors originating from a high-throughput screening campaign. Small structural changes to the hit compound increased binding affinity more than 300-fold (to IC50 w L. Surface plasmon resonance experiments afford strong evidence of binding affinity within the hydrophobic groove of Bcl-XL. Biological experiments using engineered Mcl-1 deficient mouse embryonic fibroblasts (MEFs, reliant only on Bcl-XL for survival) and Bax/Bak deficient MEFs (insensitive to selective activation of Bcl-2-driven apoptosis) support a mechanism-based induction of apoptosis. This manuscript describes the first series of selective small-molecule inhibitors of Bcl-XL and provides promising leads for the development of efficacious therapeutics against solid tumors and chemoresistant cancer cell lines.

Designing Structural Motifs for Clickamers: Exploiting the 1,2,3-Triazole Moiety to Generate Conformationally Restricted Molecular Architectures

Noncovalent interactions, especially hydrogen-bonding interactions as well as electrostatic forces, confined within one macromolecule are the key to designing foldamers that adopt well-defined conformations in solution. In the context of significant recent activities in the area of triazole-connected foldamers, so-called clickamers, we present a fundamental study that compares various model compounds that bear adjacent N-, O-, or F-heteroatom substituents. The interplay of attractive and repulsive interactions leads to rotational constraints around the single bonds attached to both the 1- and 4-positions of the 1,2,3-triazole moiety and should therefore be able to induce well-defined conformational preferences in higher oligomers and polymers, that is, foldamers. Various compounds were synthesized and characterized with regard to their preferred conformations in all three aggregation statesa-that is, in the gas phase, in solution as well as in the solid statea-by employing DFT calculations, NMR spectroscopic experiments, and X-ray crystallography, respectively. On the basis of the thus-obtained general understanding of the conformational behavior of the individual connection motifs, heterostructures were prepared from different motifs without affecting their distinct folding characteristics. Therefore, this work provides a kind of foldamer construction kit, which should enable the design of various clickamers with specific shape and incorporated functionality. A foldamer construction kit: Various heterostructures "clicked" together by structure-directing triazole moieties were investigated with regard to their conformational behavior. Different heteroatoms (X; see graphic) can be used to bias the conformation around the N(1)- and C(4)-connecting single bonds of the triazoles based on tunable noncovalent interactions.

[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: A new class of selective aldose reductase inhibitors

Acetic acid derivatives of [1,2,4]triazino[4,3-a]benzimidazole (TBI) were synthesized and tested in vitro and in vivo as a novel class of aldose reductase (ALR2) inhibitors. Compound 3, (10-benzyl[1,2,4]triazino[4,3-a]benzimidazol-3,4(10H)-dion-2-yl)aceti

3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives: Inhibitors of immune complex induced inflammation

3-[1-(2-Benzoxazolyl)hydrazino]propanenitrile derivatives were evaluated in the dermal and pleural reverse passive Arthus reactions in the rat. In the pleural test these compounds were effective in reducing exudate volume and accumulation of white blood cells. This pattern of activity was similar to that of hydrocortisone and different from that of indomethacin. The structural requirements for inhibiting the Arthus reactions were studied by systematic chemical modification of 1. These structure-activity relationship studies revealed that nitrogen 1' of the hydrazino group is essential for activity and must be electron rich, whereas chemical modifications of other sites of 1 had only a modest effect on activity.